Tag: Orchestra BioMed

Terumo Enhances Coronary Interventional Product Portfolio By Securing Exclusive Global Rights to Orchestra BioMed’s Virtue® Sirolimus-Eluting Balloon (SEB) through Global Strategic Partnership

TOKYO, June 13, 2019 /PRNewswire/ — Terumo Corporation (TSE: 4543), a leading global medical device manufacturer, today announced that it has secured exclusive global development and commercialization rights to Virtue® Sirolimus-Eluting Balloon (SEB) for percutaneous coronary interventions by entering into a strategic partnership with […]

Orchestra BioMed™ Receives FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon (SEB)

NEW HOPE, Pa., April 24, 2019 (GLOBE NEWSWIRE) —  Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet healthcare needs, announced today that it has secured Breakthrough Device designation by […]

Orchestra BioMed™ Strengthens Operations, R&D and Pharmaceutical Development Expertise with Key Leadership Team Additions

NEW HOPE, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions, announced today that it has […]